What is MediPines?
MediPines operates at the intersection of medical technology and emergency care, specializing in non-invasive cardiorespiratory assessment. The company's flagship innovation, the AGM100, serves as a critical diagnostic tool designed to identify respiratory impairment with high precision. By delivering actionable clinical data in under two minutes, the device addresses a significant gap in acute care settings, such as the management of COPD, pneumonia, and acute asthma. This technology is engineered to optimize healthcare workflows, allowing medical professionals to make rapid, data-backed decisions that directly enhance patient safety and clinical outcomes.
How much funding has MediPines raised?
MediPines has raised a total of $2.6M across 2 funding rounds:
Private Equity
$563K
Private Equity
$2M
Private Equity (2013): $563K, investors not publicly disclosed
Private Equity (2015): $2M, investors not publicly disclosed
Key Investors in MediPines
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for MediPines?
With the recent infusion of capital, MediPines is expected to scale its commercial operations and expand the reach of the AGM100 across global healthcare systems. The strategic focus will likely shift toward deepening market penetration in emergency departments and intensive care units where rapid diagnostic turnaround is paramount. As the company matures, further investment in clinical validation and product iteration will be essential to maintain its competitive edge in the respiratory diagnostics sector. The firm is well-positioned to capitalize on the increasing demand for efficient, non-invasive monitoring solutions that reduce the burden on hospital resources while improving the standard of care for patients suffering from acute respiratory distress.
See full MediPines company page
